Background Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being
increasingly used in routine clinical practice because of their fixed dosing and favourable …

The optimal duration of anticoagulation for venous thromboembolism (VTE) is uncertain. In
this prespecified analysis, we used data from 2 randomized trials, which compared once …

Methods The VTE Writing Group was established within THANZ and it comprised experts in
the field of thromboembolic disorders in Australia and New Zealand. All members undertook …

Background Patients with cancer‐associated venous thromboembolism (VTE) are
recommended to receive treatment with therapeutic anticoagulation for at least 3–6 months …

Guidelines are fundamental in addressing everyday clinical indications and in reporting the
current evidence-based data of related scientific investigations. At the same time, a spatial …

Clinicians have been more and more often encountering patients with venous
thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis, leading …

Rheumatoid arthritis (RA) is a chronic autoimmune joint disease with persistent systemic
inflammation. Patients with RA suffer from joint pain and physical disability, but have their …

Arterial and venous thromboses are sustained by development of intraluminal thrombi,
respectively, within the venous and arterial systems. The composition and structure of …

Background COVID-19 is associated with both venous and arterial thrombotic complications.
While prophylactic anticoagulation is now widely recommended for hospitalized patients …

Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …